Target intelligence / Profile preview

Gut microbiota-intestinal epithelium-mucosal immune system axis (GIM axis)

Target
GIM axis
Molecular classification
Other
01

Overview

The gut microbiota-intestinal epithelium-mucosal immune system axis is a tripartite functional unit that maintains intestinal homeostasis and systemic health (Belkaid & Hand, 2014, Science). The gut microbiota provides essential metabolic signals, such as short-chain fatty acids, which support the energy needs of the intestinal epithelium and promote the differentiation of regulatory T cells (Tregs) (Arpaia et al., 2013, Nature). The intestinal epithelium serves as a selective barrier, utilizing tight junctions and mucus layers to prevent the translocation of luminal contents into the underlying lamina propria (Okumura & Takeda, 2017, Nature Reviews Immunology). Within the mucosal immune system, specialized cells like dendritic cells and M cells sample antigens to coordinate appropriate immune responses, balancing tolerance toward commensals with defense against pathogens (Mowat & Agace, 2014, Nature Reviews Immunology). Disruptions in this axis, often termed dysbiosis or "leaky gut," are linked to the pathogenesis of inflammatory bowel disease, obesity, and various autoimmune conditions (Levy et al., 2017, Nature Reviews Immunology). Pharmacological and dietary interventions, including probiotics, fecal transplants, and biologics targeting specific cytokines, aim to recalibrate this system to restore health (Cunningham et al., 2021, Nature Reviews Gastroenterology & Hepatology).

Other names
Gut-immune axisIntestinal mucosal barrier systemMicrobiota-host interfaceGut-immune-epithelial interface
02

Mechanism of action

Modulation of microbial composition, enhancement of epithelial barrier integrity, and regulation of mucosal inflammatory signaling.

03

Biological functions

Immune responseSignal transductionBarrier functionMetabolic regulationOther
04

Disease associations

InflammationInfectionMetabolic diseaseAutoimmune diseaseOther
05

Safety considerations

Risk of systemic infection (bacteremia) with live biotherapeuticsImmune-related adverse events from biologicsVariability in patient response due to individual microbiome differencesPotential for unintended systemic immune suppression
06

Interacting drugs

Vedolizumab

5 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinMicrobial Shannon diversity indexSecretory IgAShort-chain fatty acids (SCFAs)

Beyond the preview

Go deeper on Gut microbiota-intestinal epithelium-mucosal immune system axis (GIM axis).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota-intestinal epithelium-mucosal immune system axis (GIM axis).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call